根據最新的財務報表(Form-10K),ACRO Biomedical Co Ltd 的總資產為 $0,淨損失為 $0
ACBM 的關鍵財務比率是什麼?
ACRO Biomedical Co Ltd 的流動比率為 0,淨利潤率為 0,每股銷售為 $0。
ACRO Biomedical Co Ltd 的收入按細分市場或地理位置如何劃分?
ACRO Biomedical Co Ltd 最大收入來源為 Small Molecule Drugs,在最近的收益報告中收入為 67,635,000。就地區而言,United States 是 ACRO Biomedical Co Ltd 的主要市場,收入為 67,635,000。
ACRO Biomedical Co Ltd 是否盈利?
無,根據最新的財務報表,ACRO Biomedical Co Ltd 的淨損失為 $0
ACRO Biomedical Co Ltd 有負債嗎?
無,ACRO Biomedical Co Ltd 的負債為 0
ACRO Biomedical Co Ltd 的流通股有多少?
ACRO Biomedical Co Ltd 的總流通股為 60.04
關鍵數據
前收市價
$0.026
開盤價
$0.026
當日範圍
$0.026 - $0.026
52週區間
$0.0007 - $0.036
交易量
66
平均成交量
55
股息收益率
--
每股盈餘 (TTM)
-0.00
市值
$1.5M
什麼是 ACBM?
Acro Biomedical Co. Ltd. engages in the business of developing and marketing nutritional products that promote wellness and a healthy lifestyle. The company is headquartered in Fishers, Indiana. The company went IPO on 2016-06-23. The firm is focused on developing and marketing nutritional products that promote wellness and a healthy lifestyle. The firm's business consists of selling cordyceps related products that is used in traditional Chinese medicine. Cordyceps is a fungus which is a combination of a caterpillar and a fungus, which is found at altitudes above 4500 meters (m) in Sikkim. The firm is engaged in the purchase of products from three suppliers in Taiwan and the sale of these products to four unrelated customers. The company sells products in bulk to companies who may use the Company's products as ingredients in their products or sell the products they purchase from the Company to their own customers.